CN108125967A - A kind of dressing and preparation method for being used to alleviate psoriasis - Google Patents
A kind of dressing and preparation method for being used to alleviate psoriasis Download PDFInfo
- Publication number
- CN108125967A CN108125967A CN201711419203.4A CN201711419203A CN108125967A CN 108125967 A CN108125967 A CN 108125967A CN 201711419203 A CN201711419203 A CN 201711419203A CN 108125967 A CN108125967 A CN 108125967A
- Authority
- CN
- China
- Prior art keywords
- parts
- dressing
- psoriasis
- water
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of for alleviating the dressing of psoriasis, raw material includes：Salicylic acid, Sodium Hyaluronate, glycerine, allantoin, pentanediol, xanthans, vaseline, cetostearyl alcohol, stearine, Butyrospermum parkii fruit fat, synthesis saualane, caprylic/capric triglyceride and water.The invention also includes the preparation methods of the dressing.The dressing of the present invention peomotes skin cell metabolism, slows down the fast breeding of Skin Cell, and cutin-softening promotes cutin to come off, slow down the desquamation of skin, adjust sebum secretion, enhance skin smoothness, mitigate the inflammation of psoriasis, alleviate the scales of skin that peel off and the symptom of itching.Compared with existing steroids externally applied drug, curative effect is good, Small side effects, and safety is good.
Description
Technical field
The invention belongs to external-applied ointment technical fields, and in particular to a kind of dressing and preparation side for being used to alleviate psoriasis
Method.
Background technology
Psoriasis is commonly called as " psoriasis ", is a kind of common proliferative, has the imflammatory erythema scales of skin that peel off skin of tendency of recurrence
Disease is broadly divided into psoriasis vulgaris, useless fellow psoriasis pustulosa, joint psoriasis pustulosa and red integumentary pattern psoriasis, and initiation reason is numerous,
In recent years it may be pathogenic factor that most of experts research, which thinks that heredity, metabolism barrier, infection, immunization barrier are damaged etc.,.
Psoriatic tissue pathological characteristics are mainly shown as the hyperplasia of keratinocyte, inflammatory cell aggregation and true
Skin pars papillaris blood vessel hyperplasia expansion etc., is apt to occur in four limbs and stretches side, scalp and back, serious skin lesion can general hair whole body, and may occur in which
High fever, warts, erythroderma sample changes and whole body size arthropathy.Psoriatic's skin situation is poor, due to cutin shape
Into cell hyperplasia, cause the scales of skin that peel off more, have dry skin, local inflammation aggregation causes that subregion is rubescent, even ulceration knot
Scab, and with pruritis.
There are many external used medicine for treating psoriasis, and current external used medicine belongs to hormone medicine mostly, although in short-term
Interior therapeutic effect is preferable, but over the course for the treatment of skin will appear atrophy, telangiectasis, burning heat sensation, itch, oedema,
The different degrees of adverse reactions such as dry and erythema, and easily repeatedly.
Invention content
It is an object of the invention to overcome the problems, such as that existing drug exists, and provide the use of a kind of good effect but Small side effects
In the dressing of alleviation psoriasis, while additionally provide the preparation method of the dressing.
What first purpose of the present invention was realized in：The dressing includes the raw material of following parts by weight：Salicylic acid 10~
25 parts, 0.5~2.5 part of Sodium Hyaluronate, 30~80 parts of glycerine, 1~3 part of allantoin, 20-40 parts of pentanediol, xanthans 2~5
Part, 25~35 parts of vaseline, 10~25 parts of cetostearyl alcohol, 5~15 parts of stearine, Butyrospermum parkii fruit fat 40~60
Part, synthesize 20~40 parts of saualane, 20~50 parts of caprylic/capric triglyceride, 650~820 parts of water.
In the dressing of the present invention, the primary efficacy effect of each constituent is as follows：
Glycerine is as moisturizer and dispersant dispersion thickener xanthans in 1.A components；Allantoin can mainly soften angle
Matter, aquation moisture absorption and antipruritic can also accelerate stripping off for the scales of skin that peel off.
Grease main function in 2.B components is the environment that moistening is provided for dry skin, prevents from chapping.
Salicylic acid main function is because the pH value with weak acid reduced performance keratoderma makes hyperkeratinization in 3.C components
Horn cell come off, and the growth of microorganism at skin lesion can be inhibited, while pass through oxygen hydrogen bond in its distinctive hydroxyl and carboxyl
Fracture play the role of water lock, soften the cuticula of hyperkeratinization, slow down dry skin and furfur；Sodium Hyaluronate
Main function is can to form one layer of ventilative film in skin surface, moistens skin smooth, and can obstruct alien bacteria, dust
Intrusion, protect the skin from encroaching on, and hyaluronic acid have stronger water suction and water retention property, the life of Skin Cell can be improved
Dis environment promotes the metabolism of skin histology, and skin is made to get well state；Pentanediol main function is moisturizing and inhibits micro-
The growth of biology.
Preferably, salicylic acid uses salicylic acid SA-200.Due to the dissolubility (0.2g/ of common salicylic acid in water
20 DEG C of 100mL at) it is low, the solvent or potential stimulation used makes salicylic acid be unable to reach effective concentration, also salicylic acid
Low pH value can cause stimulation and the drying of user's skin etc. uncomfortable；And the dissolubilities of salicylic acid SA-200 in water are fine,
In the product, also salicylic acid SA-200 permeability is slow for use that can be very stable, and can reduce potentially stimulates skin
With provide close to skin pH value.
The raw material weight component of dressing of the present invention is preferably：15 parts of salicylic acid -200,1.5 parts of Sodium Hyaluronate, glycerine 50
Part, 2.5 parts of allantoin, 30 parts of pentanediol, 2 parts of xanthans, 25 parts of vaseline, 18 parts of cetostearyl alcohol, stearine 11
Part, 45 parts of Butyrospermum parkii fruit fat synthesizes 30 parts of saualane, 35 parts of caprylic/capric triglyceride, 740 parts of purified water.
The raw material weight component of dressing of the present invention is also preferably：18 parts of salicylic acid -200,2 parts of Sodium Hyaluronate, glycerine 65
Part, 1.5 parts of allantoin, 20 parts of pentanediol, 3 parts of xanthans, 35 parts of vaseline, 20 parts of cetostearyl alcohol, stearine 10
Part, 50 parts of Butyrospermum parkii fruit fat synthesizes 35 parts of saualane, 25 parts of caprylic/capric triglyceride, 720 parts of purified water.
The raw material weight component of dressing of the present invention is also preferably：23 parts of salicylic acid -200,2.4 parts of Sodium Hyaluronate, glycerine
75 parts, 2.5 parts of allantoin, 35 parts of pentanediol, 4 parts of xanthans, 30 parts of vaseline, 20 parts of cetostearyl alcohol, stearine
13 parts, 55 parts of Butyrospermum parkii fruit fat synthesizes 25 parts of saualane, 45 parts of caprylic/capric triglyceride, 670 parts of purified water.
The raw material weight component of dressing of the present invention is also preferably：20 parts of salicylic acid -200,1.6 parts of Sodium Hyaluronate, glycerine
60 parts, 3 parts of allantoin, 25 parts of pentanediol, 2.5 parts of xanthans, 28 parts of vaseline, 15 parts of cetostearyl alcohol, stearine
15 parts, 60 parts of Butyrospermum parkii fruit fat synthesizes 25 parts of saualane, 30 parts of caprylic/capric triglyceride, 720 parts of purified water.
What second object of the present invention was realized in：The preparation method of the dressing is：It will warm up 80 ± 5 DEG C of A
Component and the B component mixing for being heated to 75 ± 2 DEG C, and emulsifying obtains mixed liquor, and mixed liquor then is cooled to 70 ± 2
DEG C, then stood after component C addition is sufficiently stirred to obtain the final product；Wherein：
Component A is：Purified water, glycerine, allantoin and xanthans mixture；
B component is：Vaseline, cetostearyl alcohol, stearine, Butyrospermum parkii fruit fat, synthesis saualane, octanoic acid/
The mixture of Triglyceride DDD；
Component C is：The mixture of salicylic acid SA-200, Sodium Hyaluronate and pentanediol.
In addition, in inventive formulation system, suitable anti-corrosion can also be added in the dressing prepared as needed
Agent, to extend the shelf-life of dressing.
The dressing of the present invention peomotes skin cell metabolism, slows down the fast breeding of Skin Cell, and soften
Cutin promotes cutin to come off, and slows down the desquamation of skin, adjusts sebum secretion, enhances skin smoothness, mitigates the inflammation of psoriasis, delays
Solve the scales of skin that peel off and the symptom of itching.Compared with existing steroids externally applied drug, Small side effects, safety is good.
Description of the drawings
Fig. 1 is the skin condition figure of each experimental group of zoopery；
Fig. 2 is the 20X light microscopic figures of each experimental group of zoopery；
Fig. 3 is the 20X light microscopic figures that different salicylic acid dosages compare psoriasis curative effect.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and detailed description, but the present invention is not limited to
These embodiments.
The raw material of dressing of the present invention is divided into following three component：
Component A is：650~820 parts of purified water, 30~80 parts of glycerine, 2~5 parts of 1~3 part of allantoin and xanthans it is mixed
Close object；
B component is：25~35 parts of vaseline, 10~25 parts of cetostearyl alcohol, 5~15 parts of stearine, butter fruit
Set 40~60 parts of fruit fat, synthesis saualane 20~40,20~50 parts of caprylic/capric triglyceride mixture；
Component C is：The mixing of 10~25 parts of salicylic acid SA-200,0.5~2.5 part of Sodium Hyaluronate and pentanediol 20-40
Object.
Component A is added in kettle, is heated to 80 ± 5 DEG C；B component is added in oil cauldron, and is heated to 75 ± 2 DEG C；By A
Grouping solution mixes, and 15 ± 2min of emulsifying with B component solution in pot is emulsified；Above-mentioned dressing is cooled to 70 ± 2 DEG C,
It adds in after component C is sufficiently stirred 15min and stands to obtain the final product.
The dressing of the present invention has good therapeutic effect, and the dressing of the present invention is tested on mouse body, tries
Object is tested as 30 BALB/c female mices, without pregnant, 6~8w of age, 20~30g of weight is in a good state of health.
Test method is：Imiquimod inducing mouse back forms psoriasis model.
The specific steps are：
1. the BALB/c female mices that will be in a good state of health, amobarbital is tingle liquor-saturated, and back shaving, area is at least about
2cm × 3cm sizes.
2. subjects are randomly divided into blank group, model group, test group, control group, blank group is normal skin, model
Group is psoriasis affected skin, and test group is dressing treatment skin of the present invention, and control group treats skin for salicylate compound borneol.
3. smearing isodose soft petroleum ointment after naive mice shaving, blank group does not do any place after smearing vaseline
Reason.Model group, test group, the imiquimod cream that the equal use quality score of mouse of control group is 5% are applied to mouse back
Shaving skin carries out psoriasis modeling, and after drug fully absorbs, model group smears physiological saline, 1 time a day, continuous 10 days；
Test group smears dressing of the present invention, uniformly smears a thin layer, once a day, continuous 10 days every time；Control group smears compound bigcatkin willow
Sour borneol ointment, 1 time a day, continuous 10 days.
As shown in Figure 1, 2, what Fig. 1 was shown is blank group, model group, test group, control group camera respectively to experimental result
Under figure, what Fig. 2 was shown is the figure under blank group, model group, test group, control group 20X light microscopics respectively.It can by experimental result
Know, model group is covered with the scales of skin that peel off compared with blank group skin histology plumpness, almost all skin lesion surface, the thicker stratification of the scales of skin that peel off, and stratum granulosum is thin
Born of the same parents' generation is more, there is more inflammatory cell；For test group compared with blank group, difference is not it is obvious that stratum granulosum and blank group
Equally, corium, epidermal junction are it is clear that be covered with seldom scales of skin that peel off；Control group compared with model group, otherness be not it is obvious that
Skin histology is still more plump, and most of skin lesion surfaces are covered with the scales of skin that peel off completely, and it is unapparent that stratum granulosum generates more symptom
Alleviate, and corium has more inflammatory cell infiltration.
From experimental result it is found that the dressing of the present invention is better than salicylate compound borneol ointment in terms of psoriasis is alleviated, and
Safety is higher over the course for the treatment of.
Each component dosage is changed according to the following table 1, dressing embodiments 1-4 of the present invention and comparative example is prepared, passes through animal experiment
Influence of the different formulations to alleviation psoriasis, safety is compared, test method forms silver-colored bits for imiquimod inducing mouse back
Disease model.
Embodiment 1-4 formula such as following table (unit is parts by weight)
Result of the test is as shown in figure 3, as seen from the experiment, salicylic acid SA-200 ratios are at 15,18 parts in embodiment 1,2
When, stratum granulosum is thicker, but than not adding the stratum granulosum of salicylic acid SA-200 dressing thin, has less inflammatory cell；Embodiment 3,4
Middle salicylic acid SA-200 ratios stratum granulosum at 20,23 parts is relatively thin, has less inflammatory cell infiltration.Since salicylic acid rises most
Main bacteriostasis, it can be inferred that the higher effect to alleviating psoriasis of salicylic acid SA-200 ratios is better, while not shadow
Ring the safety of dressing.
Above-described embodiment is only intended to clearly illustrate done citing, and is not intended to limit the embodiments.For institute
For the general technical staff in category field, other various forms of variations or change can also be made on the basis of the above description
It is dynamic.There is no necessity and possibility to exhaust all the enbodiments, and the obvious variation or change thus amplified out
Among moving still in the invention scope of the claims.
Claims (8)
1. a kind of dressing for being used to alleviate psoriasis, which is characterized in that include the raw material of following parts by weight：10 ~ 25 parts of salicylic acid,
0.5 ~ 2.5 part of Sodium Hyaluronate, 30 ~ 80 parts of glycerine, 1 ~ 3 part of allantoin, 20-40 parts of pentanediol, 2 ~ 5 parts of xanthans, vaseline
25 ~ 35 parts, 10 ~ 25 parts of cetostearyl alcohol, 5 ~ 15 parts of stearine, 40 ~ 60 parts of Butyrospermum parkii fruit fat, synthesis saualane 20
~ 40 parts, 20 ~ 50 parts of caprylic/capric triglyceride, 650 ~ 820 parts of water.
2. the dressing according to claim 1 for being used to alleviate psoriasis, which is characterized in that the salicylic acid uses salicylic acid
SA-200。
It is 3. according to claim 2 for alleviating the dressing of psoriasis, which is characterized in that its raw material weight component is：Water
15 parts of poplar acid SA-200,1.5 parts of Sodium Hyaluronate, 50 parts of glycerine, 2.5 parts of allantoin, 30 parts of pentanediol, 2 parts of xanthans are all
25 parts of intellectual circle, 18 parts of cetostearyl alcohol, 11 parts of stearine, 45 parts of Butyrospermum parkii fruit fat synthesize 30 parts of saualane, pungent
35 parts of acid/Triglyceride DDD, 740 parts of water.
It is 4. according to claim 2 for alleviating the dressing of psoriasis, which is characterized in that its raw material weight component is：Water
18 parts of poplar acid SA-200,2 parts of Sodium Hyaluronate, 65 parts of glycerine, 1.5 parts of allantoin, 20 parts of pentanediol, 3 parts of xanthans, all scholars
35 parts of woods, 20 parts of cetostearyl alcohol, 10 parts of stearine, 50 parts of Butyrospermum parkii fruit fat, 35 parts of saualane of synthesis, octanoic acid/
25 parts of Triglyceride DDD, 720 parts of water.
It is 5. according to claim 2 for alleviating the dressing of psoriasis, which is characterized in that its raw material weight component is：Water
23 parts of poplar acid SA-200,2.4 parts of Sodium Hyaluronate, 75 parts of glycerine, 2.5 parts of allantoin, 35 parts of pentanediol, 4 parts of xanthans are all
30 parts of intellectual circle, 20 parts of cetostearyl alcohol, 13 parts of stearine, 55 parts of Butyrospermum parkii fruit fat synthesize 25 parts of saualane, pungent
45 parts of acid/Triglyceride DDD, 670 parts of water.
It is 6. according to claim 2 for alleviating the dressing of psoriasis, which is characterized in that its raw material weight component is：Water
20 parts of poplar acid SA-200,1.6 parts of Sodium Hyaluronate, 60 parts of glycerine, 3 parts of allantoin, 25 parts of pentanediol, 2.5 parts of xanthans are all
28 parts of intellectual circle, 15 parts of cetostearyl alcohol, 15 parts of stearine, 60 parts of Butyrospermum parkii fruit fat synthesize 25 parts of saualane, pungent
30 parts of acid/Triglyceride DDD, 720 parts of water.
7. the dressing according to claim 1 for being used to alleviate psoriasis, which is characterized in that further include preservative.
A kind of 8. preparation method of the dressing of alleviation psoriasis as described in any one of claim 1-6, which is characterized in that packet
Include following steps：The component A that will warm up 80 ± 5 DEG C and the B component for being heated to 75 ± 2 DEG C mixing, and emulsifying is mixed
It closes liquid, mixed liquor is then cooled to 70 ± 2 DEG C, then stood after component C addition is sufficiently stirred to obtain the final product；Wherein：
Component A is：Water, glycerine, allantoin and xanthans mixture；
B component is：Vaseline, cetostearyl alcohol, stearine, Butyrospermum parkii fruit fat, synthesis saualane, caprylic/capric
The mixture of triglycerides；
Component C is：The mixture of salicylic acid, Sodium Hyaluronate and pentanediol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711419203.4A CN108125967A (en) | 2017-12-25 | 2017-12-25 | A kind of dressing and preparation method for being used to alleviate psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711419203.4A CN108125967A (en) | 2017-12-25 | 2017-12-25 | A kind of dressing and preparation method for being used to alleviate psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108125967A true CN108125967A (en) | 2018-06-08 |
Family
ID=62392786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711419203.4A Pending CN108125967A (en) | 2017-12-25 | 2017-12-25 | A kind of dressing and preparation method for being used to alleviate psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108125967A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110787077A (en) * | 2019-11-04 | 2020-02-14 | 武汉赛锐希斯科技有限公司 | Body lotion formula for daily maintenance of psoriasis skin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169297A (en) * | 1996-06-28 | 1998-01-07 | 武占元 | Medicine for external use for treatment of psoriasis |
| CN101224213A (en) * | 2008-01-10 | 2008-07-23 | 强繁英 | External coating liquid for treating various fungi, ringworm, ichthyosis, psoriasis |
| US20120219604A1 (en) * | 2009-12-09 | 2012-08-30 | Chul-Hwan Kim | Method of solubilizing poorly soluble/insoluble active material through formation of oligomer composite |
-
2017
- 2017-12-25 CN CN201711419203.4A patent/CN108125967A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169297A (en) * | 1996-06-28 | 1998-01-07 | 武占元 | Medicine for external use for treatment of psoriasis |
| CN101224213A (en) * | 2008-01-10 | 2008-07-23 | 强繁英 | External coating liquid for treating various fungi, ringworm, ichthyosis, psoriasis |
| US20120219604A1 (en) * | 2009-12-09 | 2012-08-30 | Chul-Hwan Kim | Method of solubilizing poorly soluble/insoluble active material through formation of oligomer composite |
Non-Patent Citations (1)
| Title |
|---|
| 蔡仲正: "5%水杨酸乳膏的配置", 《药学通报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110787077A (en) * | 2019-11-04 | 2020-02-14 | 武汉赛锐希斯科技有限公司 | Body lotion formula for daily maintenance of psoriasis skin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106727020A (en) | Baby's moistening skin-care frost | |
| CN102266280B (en) | Application of refined deer oil to preparation of moisture preserving cosmetics | |
| CN115554187B (en) | Mussel mucoprotein skin repairing emulsion capable of achieving wet and heat sterilization and preparation method thereof | |
| CN104147533A (en) | Blood-activating, stasis-resolving and pain-relieving cream and preparation method thereof | |
| CN105662916A (en) | Composition for repairing skin lipid film | |
| CN106309156A (en) | Ferulic acid acne fading solution and preparation method thereof | |
| CN108143646A (en) | A kind of antipruritic cream composition of glycyrrhetinic acid and preparation method thereof | |
| CN108125967A (en) | A kind of dressing and preparation method for being used to alleviate psoriasis | |
| CN105126037B (en) | A kind of ointment for treating bone fracture and injury of the extract containing natural component and preparation method thereof | |
| BR102012002991A2 (en) | anti-wart pharmaceutical composition and method for treating the wart | |
| CN109077943B (en) | Preparation method and application of octacosanol-containing liposome | |
| CN103800401B (en) | Granulation promoting healing ointment | |
| CN106109369A (en) | A kind of anti-wrinkle composition containing Hibiscus manihot L. and anti-wrinkle cream thereof | |
| WO1998046206A1 (en) | Skin cream composition | |
| CN105919886A (en) | Quick-acting wrinkle repairing emulsion and preparation method thereof | |
| PT2011504E (en) | Skin cream for treatment and/or cleaning of skin for neurodermitis | |
| WO2023030041A1 (en) | Type i collagen production accelerant | |
| CN108567782A (en) | A kind of posaconazole externally-applied medicinal composition, preparation method and the usage | |
| CN108379212B (en) | Camel milk moisturizing cream with anti-aging effect and preparation method thereof | |
| CN106138083A (en) | A kind of treat the herbal mixture nanometer emulsifiable paste that skin is chapped from the cold | |
| CN106163498A (en) | The topical formulations of heparin | |
| CN106074365B (en) | A kind of capsaicine ethosome gel and preparation method thereof | |
| JP7396585B2 (en) | Composition for suppressing TSLP gene expression, suppressing IL-33 gene expression, or promoting filaggrin production | |
| RU2407535C2 (en) | Biologically-active agent for dermatoses treatment | |
| CN106539804A (en) | A kind of molecule traditional Chinese medicine frostlike-powder for relief from osteoarthritis pain and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180608 |
|
| RJ01 | Rejection of invention patent application after publication |